Enliven Therapeutics (ELVN) Institutional Ownership $25.43 -0.75 (-2.86%) (As of 11/20/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Enliven Therapeutics (NASDAQ:ELVN)CurrentInstitutional OwnershipPercentage95.08%Number ofInstitutional Buyers(last 12 months)28TotalInstitutional Inflows(last 12 months)$69.93MNumber ofInstitutional Sellers(last 12 months)13TotalInstitutional Outflows(last 12 months)$57.12M Get ELVN Insider Trade Alerts Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ELVN Institutional Buying and Selling by Quarter Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Enliven Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC56,217$1.44M0.0%+295.8%0.115% 11/16/2024 Geode Capital Management LLC750,208$19.16M0.0%+9.9%1.588% 11/15/2024 Barclays PLC56,217$1.44M0.0%+295.8%0.119% 11/15/2024 Jane Street Group LLC30,793$786K0.0%-41.9%0.065% 11/15/2024 Wellington Management Group LLP70,170$1.79M0.0%+107.0%0.149% 11/15/2024 State Street Corp745,944$19.05M0.0%+2.9%1.579% Get the Latest News and Ratings for ELVN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024 RA Capital Management L.P.1,061,233$27.10M0.3%-50.0%2.246% 11/15/2024 Patient Square Capital LP90,572$2.31M0.9%N/A0.192% 11/15/2024 Ikarian Capital LLC499,566$12.76M1.7%-14.8%1.058% 11/15/2024 Janus Henderson Group PLC1,041,724$26.61M0.0%+43.0%2.205% 11/15/2024 HighVista Strategies LLC112,459$2.87M1.0%-6.1%0.238% 11/14/2024 Verition Fund Management LLC10,610$271K0.0%N/A0.022% 11/14/2024 Walleye Capital LLC99,416$2.54M0.0%N/A0.210% 11/14/2024 UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC26,168$668K0.0%+12.7%0.055% 11/14/2024 Ally Bridge Group NY LLC234,856$6.00M3.2%N/A0.497% 11/14/2024 Acuta Capital Partners LLC296,368$7.57M6.1%-25.5%0.627% 11/13/2024 FMR LLC6,296,179$160.80M0.0%+10.6%13.328% 11/13/2024 The Manufacturers Life Insurance Company 17,282$441K0.0%+25.6%0.037% 11/12/2024 Charles Schwab Investment Management Inc.255,277$6.52M0.0%+10.4%0.540% 11/7/2024 First Turn Management LLC535,092$13.67M2.2%+29.5%1.133% 11/7/2024 Quest Partners LLC21,117$539K0.0%+1,226.4%0.045% 10/25/2024 China Universal Asset Management Co. Ltd.9,085$232K0.0%+64.4%0.019% 10/10/2024 Exchange Traded Concepts LLC7,483$191K0.0%-60.3%0.016% 10/3/2024 SG Americas Securities LLC10,013$256K0.0%N/A0.021% 8/15/2024 The Manufacturers Life Insurance Company13,764$322K0.0%N/A0.029% 8/14/2024 Marshall Wace LLP192,100$4.49M0.0%N/A0.408% 8/14/2024 Logos Global Management LP595,000$13.91M1.1%-62.2%1.265% 8/14/2024 HighVista Strategies LLC119,789$2.80M1.0%-5.6%0.255% 8/8/2024 First Turn Management LLC413,243$9.66M1.6%N/A0.879% 8/8/2024 Nicholas Investment Partners LP56,072$1.31M0.1%N/A0.119% 8/8/2024 American Century Companies Inc.27,651$646K0.0%+44.7%0.059% 8/6/2024 Quest Partners LLC1,592$37K0.0%+87.3%0.003% 8/1/2024 Rhumbline Advisers49,627$1.16M0.0%+29.9%0.105% 7/26/2024 Bank of New York Mellon Corp114,109$2.67M0.0%+49.2%0.243% 5/16/2024 California State Teachers Retirement System19,141$337K0.0%-5.8%0.041% 5/16/2024 Janus Henderson Group PLC713,911$12.60M0.0%+74.8%1.519% 5/16/2024 Blackstone Inc.25,191$443K0.0%N/A0.054% 5/15/2024 Baker BROS. Advisors LP114,833$2.02M0.0%N/A0.244% 5/14/2024 EntryPoint Capital LLC9,510$167K0.1%N/A0.020% 5/10/2024 Vanguard Group Inc.1,183,266$20.81M0.0%-3.9%2.517% This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry.5/7/2024 SG Americas Securities LLC9,430$166K0.0%-30.2%0.020% 4/29/2024 China Universal Asset Management Co. Ltd.7,952$140K0.0%+67.0%0.017% 2/13/2024 Tower Research Capital LLC TRC5,485$76K0.0%-18.8%0.013% 2/6/2024 AJOVista LLC2,046$28K0.0%N/A0.005% 2/6/2024 Swiss National Bank36,473$505K0.0%-10.3%0.089% 1/24/2024 Mirae Asset Global Investments Co. Ltd.12,305$170K0.0%+9.1%0.030% 1/24/2024 China Universal Asset Management Co. Ltd.4,763$66K0.0%N/A0.012% 1/12/2024 SG Americas Securities LLC13,501$187K0.0%+17.8%0.033% 1/5/2024 Exchange Traded Concepts LLC8,708$121K0.0%+34.0%0.021% 12/6/2023 Citigroup Inc.3,347$46K0.0%-69.1%0.008% 11/13/2023 FMR LLC3,676,213$50.22M0.0%-8.1%8.923% 11/8/2023 Swiss National Bank40,673$556K0.0%-17.3%0.099% 11/7/2023 Barclays PLC13,629$186K0.0%-8.1%0.033% 10/23/2023 BML Capital Management LLC50,000$683K0.6%-32.6%0.121% 10/13/2023 SG Americas Securities LLC11,460$157K0.0%N/A0.028% 8/15/2023 HighVista Strategies LLC121,073$2.47M1.1%N/A0.294% 8/15/2023 Commodore Capital LP2,348,272$47.93M5.4%+35.6%5.707% 8/11/2023 VR Adviser LLC2,230,127$45.52M7.3%+0.7%5.423% 8/10/2023 Metropolitan Life Insurance Co NY1,279$26K0.0%N/A0.003% 8/4/2023 American International Group Inc.11,235$229K0.0%N/A0.027% 8/3/2023 Bank of New York Mellon Corp80,924$1.65M0.0%+429.1%0.197% 8/2/2023 Bank of Montreal Can191,893$3.95M0.0%N/A0.467% 7/24/2023 BML Capital Management LLC74,232$1.52M1.4%-65.0%0.181% 7/20/2023 Exchange Traded Concepts LLC6,934$142K0.0%N/A0.017% 7/18/2023 Denali Advisors LLC9,900$202K0.1%N/A0.024% 6/1/2023 Prelude Capital Management LLC34,062$40K0.0%N/A0.519% 5/16/2023 Fairmount Funds Management LLC1,924,938$42.16M7.2%N/A29.353% 5/16/2023 Boxer Capital LLC710,644$15.56M0.8%N/A10.836% 5/15/2023 Commodore Capital LP1,731,365$37.92M5.8%N/A26.401% 5/15/2023 Logos Global Management LP401,229$8.79M1.3%N/A6.118% 5/12/2023 Mirabella Financial Services LLP11,670$256K0.0%N/A0.178% 5/11/2023 FMR LLC3,163,482$69.28M0.0%N/A48.239% 4/20/2023 Dorsey Wright & Associates1,237$27K0.0%N/A0.019% (Data available from 1/1/2016 forward) ELVN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ELVN shares? During the previous two years, 51 institutional investors and hedge funds held shares of Enliven Therapeutics. The most heavily invested institutionals were FMR LLC ($160.80M), Commodore Capital LP ($47.93M), VR Adviser LLC ($45.52M), Fairmount Funds Management LLC ($42.16M), RA Capital Management L.P. ($27.10M), Janus Henderson Group PLC ($26.61M), and Vanguard Group Inc. ($20.81M).Learn more on ELVN's institutional investors. What percentage of Enliven Therapeutics stock is owned by institutional investors? 95.08% of Enliven Therapeutics stock is owned by institutional investors. Learn more on ELVN's institutional investor holdings. Which institutional investors have been buying Enliven Therapeutics stock? Of the 41 institutional investors that purchased Enliven Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: FMR LLC ($3.77M), Commodore Capital LP ($2.35M), Fairmount Funds Management LLC ($1.92M), Boxer Capital LLC ($710.64K), Janus Henderson Group PLC ($618.42K), First Turn Management LLC ($535.09K), and Logos Global Management LP ($401.23K). How much institutional buying is happening at Enliven Therapeutics? Institutional investors have bought a total of 11,979,299 shares in the last 24 months. This purchase volume represents approximately $266.06M in transactions. Which Enliven Therapeutics major shareholders have been selling company stock? Of the 16 institutional investors that sold Enliven Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: RA Capital Management L.P. ($1.06M), Logos Global Management LP ($979.22K), FMR LLC ($325.40K), BML Capital Management LLC ($162.18K), Acuta Capital Partners LLC ($101.33K), Ikarian Capital LLC ($86.99K), and Vanguard Group Inc. ($47.62K). How much institutional selling is happening at Enliven Therapeutics? Institutional investors have sold a total of 2,839,828 shares in the last 24 months. This volume of shares sold represents approximately $64.84M in transactions. Related Companies Intellia Therapeutics Institutional Ownership Avadel Pharmaceuticals Institutional Ownership Delcath Systems Institutional Ownership Editas Medicine Institutional Ownership Fulcrum Therapeutics Institutional Ownership bluebird bio Institutional Ownership CRISPR Therapeutics Institutional Ownership TG Therapeutics Institutional Ownership Biohaven Institutional Ownership Axsome Therapeutics Institutional Ownership This page (NASDAQ:ELVN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELVN with Qtrade Free ELVN Stock Alerts